Aclarion (NASDAQ:ACON – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($50.00) per share and revenue of $0.02 million for the quarter.
Aclarion Price Performance
NASDAQ ACON opened at $0.77 on Tuesday. Aclarion has a twelve month low of $0.61 and a twelve month high of $231.15. The company’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $36.87.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on ACON shares. Maxim Group reiterated a “hold” rating on shares of Aclarion in a research note on Friday, December 13th. Ascendiant Capital Markets lowered their price target on Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a research report on Wednesday, November 27th.
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Further Reading
- Five stocks we like better than Aclarion
- What is a Secondary Public Offering? What Investors Need to Know
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- With Risk Tolerance, One Size Does Not Fit All
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Top Biotech Stocks: Exploring Innovation Opportunities
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
